In public assistance, providing for pain parity in Medicaid and for pain parity in commercial insurance.
Summary
SB1196 would add “pain parity” requirements to Pennsylvania’s Human Services Code for both Medicaid and commercial insurance. In Medicaid, the Department of Human Services would be prohibited from disadvantaging an FDA-approved non-opioid pain medication on the statewide preferred drug list when compared with any equivalent opioid or narcotic pain medication. The bill also bars the department from making non-opioid pain drugs subject to more restrictive prior authorization, step therapy, or other utilization controls than the least restrictive controls applied to opioid or narcotic alternatives.
For commercial insurance, the bill would require insurers to treat FDA-approved non-opioid pain medications no less favorably than opioid or narcotic pain medications in coverage, utilization management, and cost sharing. Insurers could not place a non-opioid pain drug on a higher-cost tier than the lowest cost-sharing tier used for any opioid or narcotic drug on the formulary, and they could not impose stricter coverage criteria or utilization controls on non-opioid pain drugs. The protections would apply once a drug is FDA-approved for pain treatment or management, even if it has not yet been reviewed for the Medicaid preferred drug list.
Impact
The bill would amend the Human Services Code by adding new sections governing Medicaid drug coverage and commercial insurance formularies. It would constrain the Department of Human Services’ authority over the statewide preferred drug list and managed care drug arrangements, and it would impose new coverage, prior authorization, step therapy, and tiering rules on insurers operating in Pennsylvania. The practical effect would be to create statutory parity protections for non-opioid pain medications across public and private coverage, potentially affecting prescribing, formulary design, and patient out-of-pocket costs.
Sentiment
The available record shows the bill was introduced and referred to the Senate Health and Human Services Committee, but there are no committee transcripts, recorded votes, or other legislative actions included here. Based on the bill’s structure and purpose, it appears to be a patient-access and opioid-alternative measure intended to encourage use of non-opioid pain treatments by removing insurance barriers. Because no debate or vote history is provided, there is no documented support or opposition in the supplied materials.
Contention
The main policy tension in the bill is between expanding access to non-opioid pain medications and limiting the flexibility of Medicaid administrators and insurers to manage drug costs through formularies, prior authorization, step therapy, and tiered cost sharing. Supporters would likely view the bill as promoting safer pain treatment options and reducing reliance on opioids, while critics may argue it could increase costs, reduce formulary management tools, or interfere with utilization controls used to contain spending. No specific stakeholders or objections are identified in the provided record.